Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined with TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Ivonescimab (Primary) ; Sacituzumab govitecan (Primary)
- Indications Brain metastases; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms BALISTA
- 03 Feb 2025 New trial record